MiRNA-31-5p expression in glioblastoma tissue and effects of
its replacement in glioblastoma cells

a 2015

MiRNA-31-5p expression in glioblastoma tissue and effects of its replacement in glioblastoma cells

ŠÁNA, Jiří, Andrej BEŠŠE, Jakub ONDRÁČEK, Marek VEČEŘA, Pavel FADRUS et. al.

Základní údaje

Originální název

MiRNA-31-5p expression in glioblastoma tissue and effects of its replacement in glioblastoma cells

Autoři

Vydání

106th Annual Meeting of the American Association for Cancer Research 2015, Philadelphia, 2015

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 8.556

Organizační jednotka

Středoevropský technologický institut

ISSN

Klíčová slova anglicky

miR-31-5p; glioblastoma multiforme; in vitro analyses

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 22. 10. 2015 19:36, Mgr. Petra Vychytilová, Ph.D.

Anotace

V originále

Introduction: Glioblastoma multiforme (GBM) is the most malignant primary tumor of the central nervous system of adults. Our previous study has showed significant alterations in expression of microRNAs (miRNAs) in GBM tissue. Some of these miRNAs were also correlated with overall survival, whereas miR-31-5p was the most significant, indicating its tumor suppressive functioning. In this study, miR-31-5p was studied on larger cohort of GBM patients and also in vitro of selected GBM cell lines. Patients, Cell lines and Methods: Expression of miR-31-5p was validated on cohort of 58 GBM patients and 10 samples of non-tumor brain tissue. We have increased expression level of miR-31-5p using transient transfection of specific miRNA mimic in GBM cell lines A172, U87MG, T98MG, and U251. Cell viability and proliferation were analyzed using MTT assay and cell counting, respectively. Cell cycle analyses were performed by flow-cytometry using propidium iodide. Migration and invasion potential were measured by the wound healing assay and transwell invasion assay, respectively. Finally, potential targets of miR-31-5p were discovered using combination of bioinformatics algorithms for target prediction and GeneChip Human Gene 2.0 ST Array (Affymetrix) whole-genome expression profiling. Results: Down-regulation of miR-31-5p was successfully validated on cohort of 58 GBM patients and 10 samples of non-tumor brain tissue (p<0.001). MiR-31-5p was significantly associated also with progression-free and overall survival of GBM patients. Transient expression of miR-31-5p led to the significant decrease of GBM cell proliferation and viability in A172, U87MG, T98G, and U251 cell lines (t-test; p < 0.05) due to the cell cycle arrest in G1 phase. Moreover, transfected A172 and U251 cells had a lower migration and invasiveness potential in comparison with control cells (t-test; p < 0.05). Finally, analysis of global gene expression profiles together with predicted mRNA targets revealed several interesting targets of miR-31-5p, which are involved in crucial signaling pathways of GBM. Conclusion: Taken together, our data suggest that miR-31-5p is not only powerful diagnostic marker as showed previously but seems to be promising therapeutic target in GBM patients.

Návaznosti

ED1.1.00/02.0068, projekt VaV

Název: CEITEC - central european institute of technology

NT13514, projekt VaV

Název: Analýza mikroRNA v glioblastomových kmenových buňkách: predikce léčebné odpovědi a identifikace nových terapeutických cílů u pacientů s glioblastomem

NT13547, projekt VaV

Název: Studium mikroRNA a genů asociovaných s procesem epiteliálně-mezenchymální tranzice jako potenciálních markerů pro predikci rizika a časný záchyt metastazování u pacientů s renálním karcinomem

NT13549, projekt VaV

Název: Vytvoření diagnostické sady cirkulujících mikroRNA pro neinvazivní časnou diagnostiku a sledování pacientů s kolorektálním karcinomem

NT13860, projekt VaV

Název: Studium signální dráhy EGFR a expresních profilů mikroRNA v predikci odpovědi na cílenou anti-EGFR terapii u pacientů s kolorektálním karcinomem s nemutovanou variantou onkogenu KRAS

Citovat

ŠÁNA, Jiří, Andrej BEŠŠE, Jakub ONDRÁČEK, Marek VEČEŘA, Pavel FADRUS, Leoš KŘEN, Hana MLČOCHOVÁ, Robert ILIEV, Jitka MLČOCHOVÁ, Petra VYCHYTILOVÁ, Renata HÉŽOVÁ, Jaroslav JURÁČEK a Ondřej SLABÝ. MiRNA-31-5p expression in glioblastoma tissue and effects of its replacement in glioblastoma cells. In 106th Annual Meeting of the American Association for Cancer Research 2015, Philadelphia. 2015. ISSN 0008-5472.

@proceedings{1298550,
   author = {Šána, Jiří and Bešše, Andrej and Ondráček, Jakub and Večeřa, Marek and Fadrus, Pavel and Křen, Leoš and Mlčochová, Hana and Iliev, Robert and Mlčochová, Jitka and Vychytilová, Petra and Héžová, Renata and Juráček, Jaroslav and Slabý, Ondřej},
   booktitle = {106th Annual Meeting of the American Association for Cancer Research 2015, Philadelphia},
   keywords = {miR-31-5p; glioblastoma multiforme; in vitro analyses},
   language = {eng},
   title = {MiRNA-31-5p expression in glioblastoma tissue and effects of its replacement in glioblastoma cells},
   year = {2015}
}

TY  - CONF
ID  - 1298550
AU  - Šána, Jiří - Bešše, Andrej - Ondráček, Jakub - Večeřa, Marek - Fadrus, Pavel - Křen, Leoš - Mlčochová, Hana - Iliev, Robert - Mlčochová, Jitka - Vychytilová, Petra - Héžová, Renata - Juráček, Jaroslav - Slabý, Ondřej
PY  - 2015
TI  - MiRNA-31-5p expression in glioblastoma tissue and effects of its replacement in glioblastoma cells
KW  - miR-31-5p
KW  - glioblastoma multiforme
KW  - in vitro analyses
N2  - Introduction: Glioblastoma multiforme (GBM) is the most malignant primary tumor of the central nervous system of adults. Our previous study has showed significant alterations in expression of microRNAs (miRNAs) in GBM tissue. Some of these miRNAs were also correlated with overall survival, whereas miR-31-5p was the most significant, indicating its tumor suppressive functioning. In this study, miR-31-5p was studied on larger cohort of GBM patients and also in vitro of selected GBM cell lines. Patients, Cell lines and Methods: Expression of miR-31-5p was validated on cohort of 58 GBM patients and 10 samples of non-tumor brain tissue. We have increased expression level of miR-31-5p using transient transfection of specific miRNA mimic in GBM cell lines A172, U87MG, T98MG, and U251. Cell viability and proliferation were analyzed using MTT assay and cell counting, respectively. Cell cycle analyses were performed by flow-cytometry using propidium iodide. Migration and invasion potential were measured by the wound healing assay and transwell invasion assay, respectively. Finally, potential targets of miR-31-5p were discovered using combination of bioinformatics algorithms for target prediction and GeneChip Human Gene 2.0 ST Array (Affymetrix) whole-genome expression profiling. Results: Down-regulation of miR-31-5p was successfully validated on cohort of 58 GBM patients and 10 samples of non-tumor brain tissue (p<0.001). MiR-31-5p was significantly associated also with progression-free and overall survival of GBM patients. Transient expression of miR-31-5p led to the significant decrease of GBM cell proliferation and viability in A172, U87MG, T98G, and U251 cell lines (t-test; p < 0.05) due to the cell cycle arrest in G1 phase. Moreover, transfected A172 and U251 cells had a lower migration and invasiveness potential in comparison with control cells (t-test; p < 0.05). Finally, analysis of global gene expression profiles together with predicted mRNA targets revealed several interesting targets of miR-31-5p, which are involved in crucial signaling pathways of GBM. Conclusion: Taken together, our data suggest that miR-31-5p is not only powerful diagnostic marker as showed previously but seems to be promising therapeutic target in GBM patients.
ER  -

ŠÁNA, Jiří, Andrej BEŠŠE, Jakub ONDRÁČEK, Marek VEČEŘA, Pavel FADRUS, Leoš KŘEN, Hana MLČOCHOVÁ, Robert ILIEV, Jitka MLČOCHOVÁ, Petra VYCHYTILOVÁ, Renata HÉŽOVÁ, Jaroslav JURÁČEK a Ondřej SLABÝ. MiRNA-31-5p expression in glioblastoma tissue and effects of its replacement in glioblastoma cells. In \textit{106th Annual Meeting of the American Association for Cancer Research 2015, Philadelphia}. 2015. ISSN~0008-5472.

Podrobný výpis o publikaci